Breaking the cycle of transmission: A human-centered approach to increase adoption and sustained use of HIV prevention among high-risk adolescent girls and young women (AGYW) in South Africa

Download findings from Breaking the Cycle of Transmission, a research effort to better understand AGYW decisions and behaviors related to HIV prevention; identify different segments to better tailor outreach; and how to reach each segment more effectively. The project uses user-centered research and human-centered design and piloting.

The HIV Prevention Market Manager (PMM), co-led by AVAC and CHAI and funded by the Bill & Melinda Gates Foundation, leads the research in partnership with behavioral research firm Final Mile, user-centered design firm Upstream Innovation and market research group Ask AfriKa, with the Surgo Foundation providing strategic guidance.

Broadly Neutralizing Antibody Combinations

Overview of the combinations of broadly neutralizing antibodies (bNAbs) under investigation in early clinical studies for HIV prevention.

Evaluating, Scaling up and Enhancing Strategies for Supporting PrEP Continuation and Effective Use

In June 2019, the Prevention Product Manager (PMM)—a joint partnership between AVAC and the Clinton Health Access Initiative (CHAI)—and Jhpiego convened a think tank to consider how best to define and measure PrEP continuation. Its recommendations included modifying current PrEP indicators, recognizing that a single definition of correct or effective use might not be possible given fluctuating and variable HIV risk.

A second think tank was held in September 2020 with the theme Evaluating, Enhancing and Scaling up Strategies for Supporting PrEP Continuation and Effective Use. This think tank explored effective and promising strategies for helping people to stay on PrEP, strategies that can be scaled up across populations and locations.

CAB-LA is a Highly Effective HIV Prevention Option; Now what?

Long-acting injectable cabotegravir (CAB-LA) is a promising new option for HIV prevention. In 2020, early results from two trials—HPTN 083 and HPTN 084—showed CAB-LA was safe and highly effective at preventing HIV when compared to daily oral TDF/FTC (Truvada) in men who have sex with men (MSM), transgender (TG) women and cisgender women. Now what? What questions remain unanswered and what support is needed now to make the growing range of prevention options feasible choices for people who may want and need them?

Broadly Neutralizing Antibody Combinations

As with antiretroviral combinations used in treatment, passive immunization of broadly neutralizing antibodies for prevention may require two or more bNAbs that target different parts of the virus. This graphic outlines the bNAb combinations being explored in early clinical studies.

AMP Study FAQ

From the two trial networks conducting the AMP Study, this document provides answers to commonly asked questions about the VRC01 antibody, details on the study design and more.

AVAC’s World AIDS Day 2020 Letter to the World

On World AIDS Day 2020, AVAC hones in on three things that are essential advocacy priorities for the present moment and in 2021.

• Program for choice.
• Pay for the healthcare workforce to achieve health equity.
• Pursue just, equitable access for COVID-19 vaccines, therapeutics and community-led prevention.

Biomedical HIV Prevention Trials: Results, milestones and more

This graphic shows the updated status of large-scale prevention trials through 2022 and the impact of COVID-19 on each trial.

Another version of this graphic is available here (same content, different visual Treatment U=U).

The Next-Generation of Biomedical Prevention: Now What

Slides presented by AVAC Executive Director Mitchell Warren at the PEPFAR Scientific Advisory Board meeting taking place over October 7-8, 2020.

Understanding the EMA Opinion and Next Steps for the Dapivirine Vaginal Ring

On July 24, 2020, the European Medicines Agency (EMA) announced a positive regulatory opinion from on the Dapivirine Vaginal Ring as an HIV prevention option for cisgender women age 18 and older. This document helps advocates to understand the steps that can and must be taken now that the EMA has provided its opinion. Read it here.